[{"address1": "Azrieli Center", "address2": "Building D 26 Harokmim Street", "city": "Holon", "zip": "5885849", "country": "Israel", "phone": "972 3 765 8585", "fax": "972 3 765 8555", "website": "https://cgen.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with na\u00efve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.", "fullTimeEmployees": 68, "companyOfficers": [{"maxAge": 1, "name": "Dr. Anat  Cohen-Dayag Ph.D.", "age": 56, "title": "CEO, President & Director", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 940384, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yaron  Turpaz M.B.A., Ph.D.", "age": 52, "title": "Senior VP & Senior Advisor of Data and Informatics Solutions", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Rivka  Schwartz", "title": "Vice President Research and Discovery", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Michelle  Mahler M.D.", "title": "Chief Medical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "irWebsite": "http://cgen.com/investors", "maxAge": 86400, "priceHint": 4, "previousClose": 2.11, "open": 2.09, "dayLow": 2.0699, "dayHigh": 2.118, "regularMarketPreviousClose": 2.11, "regularMarketOpen": 2.09, "regularMarketDayLow": 2.0699, "regularMarketDayHigh": 2.118, "beta": 2.724, "forwardPE": -19.0, "volume": 197302, "regularMarketVolume": 197302, "averageVolume": 415366, "averageVolume10days": 673510, "averageDailyVolume10Day": 673510, "bid": 2.05, "ask": 2.12, "bidSize": 100, "askSize": 100, "marketCap": 187118112, "fiftyTwoWeekLow": 0.53, "fiftyTwoWeekHigh": 3.03, "priceToSalesTrailing12Months": 5.195128, "fiftyDayAverage": 2.157, "twoHundredDayAverage": 1.64005, "currency": "USD", "enterpriseValue": 88879744, "profitMargins": -0.46316, "floatShares": 84673210, "sharesOutstanding": 89530200, "sharesShort": 1728531, "sharesShortPriorMonth": 1948358, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.019299999, "heldPercentInsiders": 0.05376, "heldPercentInstitutions": 0.15692, "shortRatio": 5.84, "shortPercentOfFloat": 0.02, "impliedSharesOutstanding": 92159400, "bookValue": 0.667, "priceToBook": 3.133433, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -16682000, "trailingEps": -0.18, "forwardEps": -0.11, "enterpriseToRevenue": 2.468, "enterpriseToEbitda": -8.172, "52WeekChange": 0.64566934, "SandP52WeekChange": 0.24688339, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "CGEN", "underlyingSymbol": "CGEN", "shortName": "Compugen Ltd.", "longName": "Compugen Ltd.", "firstTradeDateEpochUtc": 966000600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "1985262d-ab80-3c43-a2e1-6782924ab738", "messageBoardId": "finmb_166115", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.09, "targetHighPrice": 7.0, "targetLowPrice": 4.0, "targetMeanPrice": 5.0, "targetMedianPrice": 4.0, "recommendationMean": 1.3, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 3, "totalCash": 101312000, "totalCashPerShare": 1.132, "ebitda": -10875500, "totalDebt": 3125000, "quickRatio": 4.286, "currentRatio": 4.286, "totalRevenue": 36018000, "debtToEquity": 5.237, "revenuePerShare": 0.408, "returnOnAssets": -0.07165, "returnOnEquity": -0.25886, "grossMargins": 0.886, "ebitdaMargins": -0.30195, "operatingMargins": -3.31848, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-06"}]